Quarterly ResultMay 4, 2026, 04:04 PM
Biodesix Q1 Revenue $25.6M, +42%; Raises FY26 Guidance to $108-114M
AI Summary
Biodesix reported strong first-quarter 2026 financial results, with total revenue reaching $25.6 million, a 42% increase year-over-year. This growth was driven by significant increases in both Diagnostic Testing revenue (+37%) and Development Services revenue (+99%). The company also improved its gross margin to 84% and reduced its net loss by 30% to $7.8 million. Based on this performance, Biodesix raised its full-year 2026 revenue guidance to $108-114 million, reflecting a 25% growth at the midpoint.
Key Highlights
- Q1 2026 total revenue grew 42% year-over-year to $25.6 million.
- Diagnostic Testing revenue increased 37% to $22.3 million.
- Development Services revenue surged 99% to $3.3 million.
- Gross margin improved to 84% in Q1 2026.
- Net loss improved 30% to $7.8 million in Q1 2026.
- Adjusted EBITDA loss improved 35% to $4.1 million.
- Raised FY 2026 revenue guidance to $108-114 million.
- Cash and cash equivalents increased 35% to $25.6 million.